ApoE ε4 carriers have an increased risk of cardiovascular disease and Alzheimer's disease, while ApoE ε2 carriers are protected from these diseases (Corder et al., 1993; Eichner et al., 1993; Christensen et al., 2006). This evidence concerns the gene APOE and early-onset autosomal dominant Alzheimer disease.